CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer

The crucial role of CD4 + and CD8 + T cells in shaping and controlling immune responses during immune disease and cancer development has been well established and used to achieve marked clinical benefits. CD3 + CD4 - CD8 - double-negative (DN) T cells, although constituting a rare subset of peripher...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 816005
Main Authors Wu, Zhiheng, Zheng, Yu, Sheng, Jin, Han, Yicheng, Yang, Yanyan, Pan, Hongming, Yao, Junlin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 10.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The crucial role of CD4 + and CD8 + T cells in shaping and controlling immune responses during immune disease and cancer development has been well established and used to achieve marked clinical benefits. CD3 + CD4 - CD8 - double-negative (DN) T cells, although constituting a rare subset of peripheral T cells, are gaining interest for their roles in inflammation, immune disease and cancer. Herein, we comprehensively review the origin, distribution and functions of this unique T cell subgroup. First, we focused on characterizing multifunctional DN T cells in various immune responses. DN regulatory T cells have the capacity to prevent graft-versus-host disease and have therapeutic value for autoimmune disease. T helper-like DN T cells protect against or promote inflammation and virus infection depending on the specific settings and promote certain autoimmune disease. Notably, we clarified the role of DN tumor-infiltrating lymphocytes and outlined the potential for malignant proliferation of DN T cells. Finally, we reviewed the recent advances in the applications of DN T cell-based therapy for cancer. In conclusion, a better understanding of the heterogeneity and functions of DN T cells may help to develop DN T cells as a potential therapeutic tool for inflammation, immune disorders and cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Laurence Menard, Bristol Myers Squibb, United States; Peter Steinberger, Medical University of Vienna, Austria
This article was submitted to Systems Immunology, a section of the journal Frontiers in Immunology
Edited by: Peter S. Linsley, Benaroya Research Institute, United States
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.816005